Skip to content

Study · Randomized controlled trial · 2021

8 results

Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.

Riddle MC, Gerstein HC, Xavier D, Cushman WC, Leiter LA, Raubenheimer PJ, Atisso CM, Raha S, Varnado OJ, Konig M, Lakshmanan M, Franek E

The Journal of clinical endocrinology and metabolism1 Apr 2021Cited by 20 (Europe PMC)

PMID33537745 (opens in a new tab)PMCIDPMC8063250 (opens in a new tab)DOI10.1210/clinem/dgab065 (opens in a new tab)PepBankPUB-33537745
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes in REWIND, dulaglutide reduced MACE incidence by a similar amount in older and younger patients (11% vs 13%).

    In plain wordsDulaglutide lowered major cardiovascular events similarly in patients aged 65 and older and younger patients with diabetes, compared with placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMACE incidence by age
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    1.5 mgAs given in this study (human).

    Measurements

    MACE incidence reduction (as reported)
    11%
    older patients (65 years or older)
    MACE incidence reduction (as reported)
    13%
    younger patients (under 65 years)

    Source sentences

    Summary
    Dulaglutide treatment showed a similar reduction in the incidence (11% vs 13%) of MACE in older vs younger patients.
    2 context sentences
    Summary · context
    Participants included type 2 diabetes patients aged 50 years or older with established cardiovascular (CV) disease or multiple CV risk factors, and a wide range of glycemic control.
    Summary · context
    Patients were randomly assigned (1:1) to dulaglutide 1.5 mg or placebo as an add-on to country-specific standard of care.
  2. 02HumanRandomized controlled trialSafety outcome

    In each age subgroup, permanent drug discontinuation was similar with dulaglutide and placebo.

    In plain wordsIn each age subgroup, permanent drug discontinuation was similar with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changePermanent drug discontinuation
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.5 mgAs given in this study (human).

    Source sentences

    Summary
    The rate of permanent study drug discontinuation, incidence of all-cause mortality, hospitalizations for heart failure, severe hypoglycemia, severe renal or urinary events, and serious gastrointestinal events were similar between randomized treatment groups within each age subgroup.
    2 context sentences
    Summary · context
    Participants included type 2 diabetes patients aged 50 years or older with established cardiovascular (CV) disease or multiple CV risk factors, and a wide range of glycemic control.
    Summary · context
    Patients were randomly assigned (1:1) to dulaglutide 1.5 mg or placebo as an add-on to country-specific standard of care.
  3. 03HumanRandomized controlled trialSafety outcome

    In each age subgroup, all-cause mortality was similar with dulaglutide and placebo.

    In plain wordsIn each age subgroup, deaths from any cause were similar with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeAll-cause mortality
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Mortality · Whole body
    Studied dose
    1.5 mgAs given in this study (human).

    Source sentences

    Summary
    The rate of permanent study drug discontinuation, incidence of all-cause mortality, hospitalizations for heart failure, severe hypoglycemia, severe renal or urinary events, and serious gastrointestinal events were similar between randomized treatment groups within each age subgroup.
    2 context sentences
    Summary · context
    Participants included type 2 diabetes patients aged 50 years or older with established cardiovascular (CV) disease or multiple CV risk factors, and a wide range of glycemic control.
    Summary · context
    Patients were randomly assigned (1:1) to dulaglutide 1.5 mg or placebo as an add-on to country-specific standard of care.
  4. 04HumanRandomized controlled trialSafety outcome

    In each age subgroup, heart failure hospitalization was similar with dulaglutide and placebo.

    In plain wordsIn each age subgroup, hospital admissions for heart failure were similar with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHeart failure hospitalization
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.5 mgAs given in this study (human).

    Source sentences

    Summary
    The rate of permanent study drug discontinuation, incidence of all-cause mortality, hospitalizations for heart failure, severe hypoglycemia, severe renal or urinary events, and serious gastrointestinal events were similar between randomized treatment groups within each age subgroup.
    2 context sentences
    Summary · context
    Participants included type 2 diabetes patients aged 50 years or older with established cardiovascular (CV) disease or multiple CV risk factors, and a wide range of glycemic control.
    Summary · context
    Patients were randomly assigned (1:1) to dulaglutide 1.5 mg or placebo as an add-on to country-specific standard of care.
  5. 05HumanRandomized controlled trialSafety outcome

    In each age subgroup, severe hypoglycemia was similar with dulaglutide and placebo.

    In plain wordsIn each age subgroup, severe low blood sugar was similar with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSevere hypoglycemia
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    1.5 mgAs given in this study (human).

    Source sentences

    Summary
    The rate of permanent study drug discontinuation, incidence of all-cause mortality, hospitalizations for heart failure, severe hypoglycemia, severe renal or urinary events, and serious gastrointestinal events were similar between randomized treatment groups within each age subgroup.
    2 context sentences
    Summary · context
    Participants included type 2 diabetes patients aged 50 years or older with established cardiovascular (CV) disease or multiple CV risk factors, and a wide range of glycemic control.
    Summary · context
    Patients were randomly assigned (1:1) to dulaglutide 1.5 mg or placebo as an add-on to country-specific standard of care.
  6. 06HumanRandomized controlled trialSafety outcome

    In each age subgroup, severe renal or urinary events were similar with dulaglutide and placebo.

    In plain wordsIn each age subgroup, severe kidney or urinary events were similar with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSevere renal or urinary events
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    1.5 mgAs given in this study (human).

    Source sentences

    Summary
    The rate of permanent study drug discontinuation, incidence of all-cause mortality, hospitalizations for heart failure, severe hypoglycemia, severe renal or urinary events, and serious gastrointestinal events were similar between randomized treatment groups within each age subgroup.
    2 context sentences
    Summary · context
    Participants included type 2 diabetes patients aged 50 years or older with established cardiovascular (CV) disease or multiple CV risk factors, and a wide range of glycemic control.
    Summary · context
    Patients were randomly assigned (1:1) to dulaglutide 1.5 mg or placebo as an add-on to country-specific standard of care.
  7. 07HumanRandomized controlled trialSafety outcome

    In each age subgroup, serious gastrointestinal events were similar with dulaglutide and placebo.

    In plain wordsIn each age subgroup, serious digestive events were similar with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSerious gastrointestinal events
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.5 mgAs given in this study (human).

    Source sentences

    Summary
    The rate of permanent study drug discontinuation, incidence of all-cause mortality, hospitalizations for heart failure, severe hypoglycemia, severe renal or urinary events, and serious gastrointestinal events were similar between randomized treatment groups within each age subgroup.
    2 context sentences
    Summary · context
    Participants included type 2 diabetes patients aged 50 years or older with established cardiovascular (CV) disease or multiple CV risk factors, and a wide range of glycemic control.
    Summary · context
    Patients were randomly assigned (1:1) to dulaglutide 1.5 mg or placebo as an add-on to country-specific standard of care.
  8. 08HumanRandomized controlled trialSafety outcome

    In each age subgroup, serious cardiac conduction disorders were numerically higher with dulaglutide than placebo, without statistical significance.

    In plain wordsIn each age subgroup, serious heart conduction disorders were numerically higher with dulaglutide than placebo, without statistical significance.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSerious cardiac conduction disorders
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    1.5 mgAs given in this study (human).

    Source sentences

    Summary
    The incidence rate of serious cardiac conduction disorders was numerically higher in the dulaglutide group compared to placebo within each age subgroup but the difference was not statistically significant.
    2 context sentences
    Summary · context
    Participants included type 2 diabetes patients aged 50 years or older with established cardiovascular (CV) disease or multiple CV risk factors, and a wide range of glycemic control.
    Summary · context
    Patients were randomly assigned (1:1) to dulaglutide 1.5 mg or placebo as an add-on to country-specific standard of care.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01394952

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Eli Lilly and Companyn = 9,90122 Jul 2011 to 21 Aug 2018

Cardiovascular Disease · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 8 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.